Hemab Therapeutics recently announced that the first patient has been dosed in their phase 1/2 clinical trial of HMB-002, an investigational subcutaneous therapy for patients with von Willebrand disease (VWD). It is developed with a monovalent…
FOR IMMEDIATE RELEASE CONTACT: National Bleeding Disorders FoundationKyla Clark, Director of PR, Marketing and CommunicationsKclark@bleeding.org 347-920-0047 …
For Immediate Release PRESS CONTACT: Kyla Clark National Bleeding Disorders Foundation 347-920-0047kclark@bleeding.org NBDF Opens 2025 Research Grant ApplicationsAnnual Funding…
For Immediate Release PRESS CONTACT: Kyla Clark National Bleeding Disorders Foundation 347-920-0047kclark@bleeding.org Amplifying Voices: NBDF Celebrates Bleeding Disorders Awareness Month…
Dr. Christopher Ng was a pediatric hematology/oncology fellow at the University of Colorado - Anschutz Medical Campus. Dr. Ng attended medical school at the Keck School of Medicine at the University of Southern California and completed his…
Federal Updates:2025 Washington Days Last week, over 400 advocates from the bleeding disorders community took to Capitol Hill to talk with their legislators and their staff about issues important to the…
MASAC MinutesSeptember 14, 2024Atlanta, GA 1. Call to Order Dr. DunnDr. Dunn…
Webinar DescriptionJoin NBDF for an exclusive first look at the transformation of our Health Access and Strategic Innovation (HASI) team. In this webinar session, the newly rebranded HASI team will unveil their enhanced identity and…
Let’s Talk About The Importance of Participating in ResearchDescription:For many in the bleeding disorder community, research is an important subject, but not everyone wants to participate in research. In this webinar, we will…
The National Bleeding Disorders Foundation (NBDF) is proud to share its latest work on health equity, diversity, and inclusion, published in Health Equity (Vol. 9, No. 1). This research highlights the barriers…